PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
OLMA vs. TSHA
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between OLMA and TSHA is 0.29, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.3

Performance

OLMA vs. TSHA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Olema Pharmaceuticals, Inc. (OLMA) and Taysha Gene Therapies, Inc. (TSHA). The values are adjusted to include any dividend payments, if applicable.

-60.00%-40.00%-20.00%0.00%20.00%40.00%AugustSeptemberOctoberNovemberDecember2025
-62.74%
-33.15%
OLMA
TSHA

Key characteristics

Sharpe Ratio

OLMA:

-0.63

TSHA:

-0.03

Sortino Ratio

OLMA:

-0.68

TSHA:

0.83

Omega Ratio

OLMA:

0.92

TSHA:

1.10

Calmar Ratio

OLMA:

-0.55

TSHA:

-0.04

Martin Ratio

OLMA:

-1.44

TSHA:

-0.09

Ulcer Index

OLMA:

34.51%

TSHA:

39.13%

Daily Std Dev

OLMA:

79.46%

TSHA:

111.21%

Max Drawdown

OLMA:

-96.26%

TSHA:

-98.14%

Current Drawdown

OLMA:

-89.61%

TSHA:

-95.18%

Fundamentals

Market Cap

OLMA:

$420.22M

TSHA:

$323.81M

EPS

OLMA:

-$2.44

TSHA:

$0.61

Total Revenue (TTM)

OLMA:

$0.00

TSHA:

$6.31M

Gross Profit (TTM)

OLMA:

-$182.00K

TSHA:

$5.69M

EBITDA (TTM)

OLMA:

-$105.21M

TSHA:

-$69.51M

Returns By Period

In the year-to-date period, OLMA achieves a -2.92% return, which is significantly higher than TSHA's -11.56% return.


OLMA

YTD

-2.92%

1M

-7.21%

6M

-62.64%

1Y

-49.82%

5Y*

N/A

10Y*

N/A

TSHA

YTD

-11.56%

1M

-17.30%

6M

-29.82%

1Y

6.25%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

OLMA vs. TSHA — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

OLMA
The Risk-Adjusted Performance Rank of OLMA is 1414
Overall Rank
The Sharpe Ratio Rank of OLMA is 1414
Sharpe Ratio Rank
The Sortino Ratio Rank of OLMA is 1616
Sortino Ratio Rank
The Omega Ratio Rank of OLMA is 1717
Omega Ratio Rank
The Calmar Ratio Rank of OLMA is 1414
Calmar Ratio Rank
The Martin Ratio Rank of OLMA is 77
Martin Ratio Rank

TSHA
The Risk-Adjusted Performance Rank of TSHA is 4747
Overall Rank
The Sharpe Ratio Rank of TSHA is 4444
Sharpe Ratio Rank
The Sortino Ratio Rank of TSHA is 5454
Sortino Ratio Rank
The Omega Ratio Rank of TSHA is 5252
Omega Ratio Rank
The Calmar Ratio Rank of TSHA is 4343
Calmar Ratio Rank
The Martin Ratio Rank of TSHA is 4444
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

OLMA vs. TSHA - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Olema Pharmaceuticals, Inc. (OLMA) and Taysha Gene Therapies, Inc. (TSHA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for OLMA, currently valued at -0.63, compared to the broader market-2.000.002.004.00-0.63-0.03
The chart of Sortino ratio for OLMA, currently valued at -0.68, compared to the broader market-4.00-2.000.002.004.006.00-0.680.83
The chart of Omega ratio for OLMA, currently valued at 0.92, compared to the broader market0.501.001.502.000.921.10
The chart of Calmar ratio for OLMA, currently valued at -0.55, compared to the broader market0.002.004.006.00-0.55-0.04
The chart of Martin ratio for OLMA, currently valued at -1.44, compared to the broader market-10.000.0010.0020.0030.00-1.44-0.09
OLMA
TSHA

The current OLMA Sharpe Ratio is -0.63, which is lower than the TSHA Sharpe Ratio of -0.03. The chart below compares the historical Sharpe Ratios of OLMA and TSHA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-0.500.000.501.00AugustSeptemberOctoberNovemberDecember2025
-0.63
-0.03
OLMA
TSHA

Dividends

OLMA vs. TSHA - Dividend Comparison

Neither OLMA nor TSHA has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

OLMA vs. TSHA - Drawdown Comparison

The maximum OLMA drawdown since its inception was -96.26%, roughly equal to the maximum TSHA drawdown of -98.14%. Use the drawdown chart below to compare losses from any high point for OLMA and TSHA. For additional features, visit the drawdowns tool.


-95.00%-90.00%-85.00%-80.00%-75.00%-70.00%AugustSeptemberOctoberNovemberDecember2025
-89.61%
-95.18%
OLMA
TSHA

Volatility

OLMA vs. TSHA - Volatility Comparison

Olema Pharmaceuticals, Inc. (OLMA) has a higher volatility of 27.83% compared to Taysha Gene Therapies, Inc. (TSHA) at 21.52%. This indicates that OLMA's price experiences larger fluctuations and is considered to be riskier than TSHA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%50.00%60.00%AugustSeptemberOctoberNovemberDecember2025
27.83%
21.52%
OLMA
TSHA

Financials

OLMA vs. TSHA - Financials Comparison

This section allows you to compare key financial metrics between Olema Pharmaceuticals, Inc. and Taysha Gene Therapies, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab